Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Soluble guanylate cyclase modulators in heart failure.

Literature DB >> 21207207

Soluble guanylate cyclase modulators in heart failure.

Veselin Mitrovic¹, Ana Jovanovic, Stefan Lehinant.

Abstract

This review summarizes the role of soluble guanylate cyclase (sGC)-cyclic guanosine 3', 5'-monophosphate pathways in heart failure and several new drugs that modify guanylate cyclase. The sGC activators and stimulators as modulators of sGC are promising drugs in the therapy for decompensated heart failure and pulmonary hypertension. Cinaciguat is a nitric oxide (NO)-independent direct activator of sGC, which also may be effective under oxidative stress conditions resulting in oxidized or heme-free sGC refractory to organic nitrates. Riociguat is an NO-independent direct stimulator of sGC with beneficial effects in patients with decompensated heart failure and pulmonary hypertension. The sGC modulators play an important role in patients with heart failure and pulmonary hypertension.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21207207 DOI： 10.1007/s11897-010-0045-1

Source DB: PubMed Journal: Curr Heart Fail Rep ISSN： 1546-9530

28 in total

Review 1. Guanylyl cyclases and signaling by cyclic GMP.

Authors: K A Lucas; G M Pitari; S Kazerounian; I Ruiz-Stewart; J Park; S Schulz; K P Chepenik; S A Waldman
Journal: Pharmacol Rev Date: 2000-09 Impact factor: 25.468

2. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.

Authors: Erland Erdmann; Marc J Semigran; Markku S Nieminen; Mihai Gheorghiade; Rahul Agrawal; Veselin Mitrovic; Alexandre Mebazaa
Journal: Eur Heart J Date: 2012-07-09 Impact factor: 29.983

3. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications.

Authors: Robert Feil; Barbara Kemp-Harper
Journal: EMBO Rep Date: 2006-02 Impact factor: 8.807

Review 4. Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations.

Authors: A Clerico; G Iervasi; A Pilo
Journal: Curr Drug Metab Date: 2000-07 Impact factor: 3.731

5. More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

Authors: S Stewart; K MacIntyre; D J Hole; S Capewell; J J McMurray
Journal: Eur J Heart Fail Date: 2001-06 Impact factor: 15.534

Review 6. Mechanisms of action of nitrates.

Authors: K E Torfgård; J Ahlner
Journal: Cardiovasc Drugs Ther Date: 1994-10 Impact factor: 3.727

7. A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits.

Authors: J Foerster; C Harteneck; J Malkewitz; G Schultz; D Koesling
Journal: Eur J Biochem Date: 1996-09-01

8. Meeting report: cGMP matters.

Authors: Barbara Kemp-Harper; Robert Feil
Journal: Sci Signal Date: 2008-03-04 Impact factor: 8.192

9. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.

Authors: Reiner Frey; Wolfgang Mück; Sigrun Unger; Ulrike Artmeier-Brandt; Gerrit Weimann; Georg Wensing
Journal: J Clin Pharmacol Date: 2008-09-08 Impact factor: 3.126

10. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.

Authors: M Volpe; C Tritto; N De Luca; A F Mele; G Lembo; S Rubattu; M Romano; P De Campora; I Enea; B Ricciardelli
Journal: J Clin Invest Date: 1991-11 Impact factor: 14.808

11 in total

1. Elucidation of cGMP-dependent induction of mitochondrial biogenesis through PKG and p38 MAPK in the kidney.

Authors: Pallavi Bhargava; Jaroslav Janda; Rick G Schnellmann
Journal: Am J Physiol Renal Physiol Date: 2019-12-16

Review 2. Novel vasodilators in heart failure.

Authors: Payman Zamani; Barry H Greenberg
Journal: Curr Heart Fail Rep Date: 2013-03

Review 3. cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.

Authors: Linda S Hoffmann; Horng H Chen
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-06-15 Impact factor: 3.000

Review 4. [Update on diagnostics and treatment of heart failure].

Authors: Jan Wintrich; Ann-Kathrin Berger; Yvonne Bewarder; Insa Emrich; Jonathan Slawik; Michael Böhm
Journal: Herz Date: 2021-08-31 Impact factor: 1.740

5. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.

Authors: Melissa H Costell; Nicolas Ancellin; Roberta E Bernard; Shufang Zhao; John J Upson; Lisa A Morgan; Kristeen Maniscalco; Alan R Olzinski; Victoria L T Ballard; Kenny Herry; Pascal Grondin; Nerina Dodic; Olivier Mirguet; Anne Bouillot; Francoise Gellibert; Robert W Coatney; John J Lepore; Beat M Jucker; Larry J Jolivette; Robert N Willette; Christine G Schnackenberg; David J Behm
Journal: Front Pharmacol Date: 2012-07-05 Impact factor: 5.810

Review 6. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.

Authors: Xiaoyu Zheng; Weijin Zheng; Bo Xiong; Jing Huang
Journal: Medicine (Baltimore) Date: 2018-10 Impact factor: 1.817